stonks4u
Sign up free
PVLA logo

PVLA Palvella Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$156.13
-0.42 (-0.27%)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcy…

Market Cap: $2.24Bpalvellatx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

70
70
Aug 16Aug 16

Quote

Day Range
$154.35 – $160.33
52-Week Range
$46.08 – $161.38
Volume
$109.8K
Market Cap
$2.24B
50-Day Avg
$137.39
200-Day Avg
$113.48
Prev Close
$156.55
Open
$156.55

Valuation & Ratios

P/E Ratio
-28.21
EPS
$-3.71
P/B Ratio
42.09
P/S Ratio
0.00
Debt/Equity
0.02
Current Ratio
5.20
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-149.1%
Return on Assets
-70.0%
FCF Yield
-2.1%
EV/EBITDA
-31.21

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-41.72M$-3.71
2024$0.00$-17.43M$-7.83
2023$0.00$18.69M$14.74
2022$25.90M$-33.28M$-29.61
2021$31.42M$-45.74M$-56.69

Social Signal Score

20
5d
21
1 mentions
—
30d
20
1 mentions
—
60d
20
1 mentions
—
90d
20
1 mentions
—
news: 1

Earnings

Tue, Nov 10(in 3 months)

Consensus estimate $-1.77 per share

2of 7 quarters beat consensus

Typical surprise -18.5% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 4$-1.52 vs $-1.17miss
  • Thu, May 7$-1.20 vs $-0.90miss
  • Tue, Mar 31$-1.08 vs $-0.91miss
  • Tue, Nov 11$-1.03 vs $-0.85miss
  • Thu, Aug 14$-0.86 vs $-0.78miss
  • Thu, May 15$-0.74 vs $-3.40beat

Estimates and results for PVLA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by PVLA officers and directors.

Bought
$951k

5 trades

Sold
$4.2m

25 trades

  • Goin Kathleensold
    Chief Operating Officer·522 @ $147.14·$77k·Jul 15, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·840 @ $148.40·$125k·Jul 15, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·1,029 @ $149.27·$154k·Jul 15, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·1,911 @ $150.25·$287k·Jul 15, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·2,390 @ $110.26·$264k·Jun 17, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·1,887 @ $111.31·$210k·Jun 17, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·25 @ $112.23·$3k·Jun 17, 2026·filing
  • Goin Kathleensold
    Chief Operating Officer·3,363 @ $110.35·$371k·May 20, 2026·filing

70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

PVLAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsmarketbeat.com·6h ago·Negative

    Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.

    View source ↗